The perils and consequences of payer step editing (“Step Therapy”) in US medical oncology: evidence, case examples, and policy remedies
Abstract
Step therapy (“fail-first”) policies require patients to initiate treatment with a payer-preferred regimen, often selected for cost, before coverage is granted for the oncologist-recommended therapy. In medical oncology, where biologic heterogeneity, biomarker-directed therapy, and time-sensitive sequencing determine outcomes, step edits can function as an avoidable barrier to evidence-based care. We performed a narrative review of peer-reviewed literature (2010-2025) and relevant US regulatory and policy documents to summarize the clinical, economic, and equity implications of step therapy as applied to systemic anticancer treatments. Evidence from cancer-specific and cross-cutting utilization management research suggests that coverage restrictions can delay initiation or continuation of therapy and increase treatment discontinuation. We synthesize mechanisms of harm (time-to-treatment delays, forced non-guideline-concordant sequencing, and toxicity exposure), describe contemporary case examples across therapeutic areas, and propose actionable policy remedies. Oncology-specific safeguards, including transparent clinical criteria, rapid exceptions and appeals, continuity-of-care protections, and provider performance-based exemptions (“gold-carding”), are essential to balance payer oversight with the imperatives of precision oncology.
Related
- The Immunological Consequences of Pediatric Adenotonsillectomy: Myths, Evidence, and Unsolved Questions.
- Cognitive Impairment in Asthma: Emerging Evidence, Clinical Consequences, and Future Directions
- Digital health misinformation in Southeast Asia: a systematic review of susceptibility, public health consequences, and intervention evidence
- Transoral Robotic Surgery in Head and Neck Oncology: A Scoping Review of Evidence, Technological Advancements, and Future Trajectories
- Choosing Between Anti-TROP2 ADCs in Advanced Breast Cancer Without Head-to-Head Evidence: A Practical Evidence-Informed Decision Framework Endorsed by the Polish Society of Clinical Oncology.
BibTeX
@article{gordan2026perils,
title = {{The perils and consequences of payer step editing (“Step Therapy”) in US medical oncology: evidence, case examples, and policy remedies}},
author = {Lucio N Gordan and Kristen Boykin and Michael Reff and Paul Chadwick and Kiana Mehring and Austin Cox and David Wenk and Matthew Fink and Josh Eaves and Ryan Ciarrocchi},
journal = {The Oncologist},
year = {2026},
month = oct,
doi = {10.1093/oncolo/oyag398},
url = {https://doi.org/10.1093/oncolo/oyag398},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - The perils and consequences of payer step editing (“Step Therapy”) in US medical oncology: evidence, case examples, and policy remedies
AU - Lucio N Gordan
AU - Kristen Boykin
AU - Michael Reff
AU - Paul Chadwick
AU - Kiana Mehring
AU - Austin Cox
AU - David Wenk
AU - Matthew Fink
AU - Josh Eaves
AU - Ryan Ciarrocchi
PY - 2026
DA - 2026/10/12
JO - The Oncologist
DO - 10.1093/oncolo/oyag398
UR - https://doi.org/10.1093/oncolo/oyag398
AB - Step therapy (“fail-first”) policies require patients to initiate treatment with a payer-preferred regimen, often selected for cost, before coverage is granted for the oncologist-recommended therapy. In medical oncology, where biologic heterogeneity, biomarker-directed therapy, and time-sensitive sequencing determine outcomes, step edits can function as an avoidable barrier to evidence-based care. We performed a narrative review of peer-reviewed literature (2010-2025) and relevant US regulatory and policy documents to summarize the clinical, economic, and equity implications of step therapy as applied to systemic anticancer treatments. Evidence from cancer-specific and cross-cutting utilization management research suggests that coverage restrictions can delay initiation or continuation of therapy and increase treatment discontinuation. We synthesize mechanisms of harm (time-to-treatment delays, forced non-guideline-concordant sequencing, and toxicity exposure), describe contemporary case examples across therapeutic areas, and propose actionable policy remedies. Oncology-specific safeguards, including transparent clinical criteria, rapid exceptions and appeals, continuity-of-care protections, and provider performance-based exemptions (“gold-carding”), are essential to balance payer oversight with the imperatives of precision oncology.
SN - 1083-7159
SN - 1549-490X
ER -